In a patient with stroke who develops central fever, should diclofenac be used as an antipyretic, and what are the appropriate dose and precautions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Diclofenac for Central Fever in Stroke: Clinical Recommendation

While diclofenac can effectively reduce body temperature in stroke patients with central fever, current guidelines provide no evidence that antipyretic treatment improves functional outcomes or survival, and diclofenac carries significant cardiovascular and hepatic risks that are particularly concerning in the acute stroke population.

Evidence-Based Framework

Guideline Position on Antipyretics in Stroke

The 2015 European Stroke Organisation (ESO) guidelines explicitly state they cannot make any recommendation for treating hyperthermia as a means to improve functional outcome and/or survival in acute ischemic stroke patients 1. This neutral stance reflects:

  • Very low to low quality evidence
  • No demonstrated benefit on mortality or functional outcomes
  • Weak strength of recommendation

The guidelines acknowledge that antipyretics may be given to relieve discomfort associated with hyperthermia, but this is distinct from improving clinical outcomes 1.

Critical Care Perspective

The 2023 Society of Critical Care Medicine guidelines suggest avoiding routine use of antipyretic medications for the specific purpose of reducing temperature in critically ill patients with fever (weak recommendation, moderate quality evidence) 2. However, they do suggest using antipyretics over nonpharmacologic methods if patients value comfort by reducing temperature 2.

Diclofenac-Specific Considerations

Efficacy Data

Research demonstrates diclofenac can effectively reduce body temperature in neurologically injured patients:

  • Low-dose continuous infusion (0.04 mg/kg/h) achieved normothermia (<37.5°C) in acute cerebral damage patients 3
  • Single IV bolus (0.2 mg/kg) reduced temperature by >0.5°C within 1 hour in 90% of ICU patients 4
  • A systematic review confirmed diclofenac reduces body temperature (mean difference 1.10°C) in neurocritical care 5

Critical Safety Concerns

Cardiovascular Risks:

  • Diclofenac increases major adverse cardiovascular events by approximately 50% (IRR 1.53) 6
  • Risk elevation occurs with both high (≥150 mg/day) and low (<150 mg/day) doses 6
  • This is particularly problematic in stroke patients who already have elevated cardiovascular risk
  • The FDA label warns of increased risk of myocardial infarction and stroke with NSAIDs 7

Hepatotoxicity:

  • Approximately 4% of patients develop meaningful ALT/AST elevations 7
  • Severe hepatic reactions including liver necrosis and fulminant hepatitis have been reported 7
  • Most elevations occur within the first 2 months but can happen anytime 7
  • Requires baseline and periodic transaminase monitoring within 4-8 weeks 7

Renal Toxicity:

  • NSAIDs can cause dose-dependent reduction in renal perfusion 7
  • Highest risk in patients with heart failure, dehydration, or on ACE inhibitors/diuretics 7
  • Common comorbidities in stroke patients

Clinical Algorithm for Decision-Making

Step 1: Establish Fever Etiology

  • Rule out infection first - obtain chest X-ray, cultures, inflammatory markers 2
  • Central fever diagnosis requires: early onset (typically day 1-3), hypothalamic/brainstem involvement, absence of infection, and negative cultures 8
  • Consider alternative diagnoses (drug fever, DVT, etc.)

Step 2: Assess Need for Treatment

Treat if:

  • Patient experiencing significant discomfort from fever
  • Temperature >38.3°C causing distress

Do NOT treat if:

  • Goal is to improve stroke outcomes (no evidence of benefit)
  • Patient is asymptomatic from fever

Step 3: Risk Stratification for Diclofenac

Absolute contraindications:

  • Recent MI or active cardiovascular disease
  • Severe heart failure
  • Hepatic dysfunction or elevated transaminases
  • Renal impairment
  • History of GI bleeding

Relative contraindications:

  • Hypertension
  • On antiplatelet agents beyond aspirin
  • Dehydration or hypovolemia

Step 4: Treatment Selection

First-line approach:

  • Acetaminophen (paracetamol) remains safer despite limited efficacy 9
  • Maximum 3 grams/day to avoid hepatotoxicity 9
  • Physical cooling methods if acetaminophen inadequate

If considering diclofenac:

Dosing regimen based on research:

  • IV bolus: 0.2 mg/kg in 100 mL saline over 30 minutes 10
  • Continuous infusion: 0.04 mg/kg/h (approximately 75 mg in 50 mL saline over 24 hours for 70 kg patient) 3
  • Alternative: 75 mg IV brief infusion 4, 11

Monitoring requirements:

  • Baseline liver function tests, renal function, CBC
  • Blood pressure monitoring
  • Repeat LFTs within 4-8 weeks if prolonged use 7
  • Assess volume status before initiation 7
  • Monitor for signs of hepatotoxicity (nausea, jaundice, RUQ pain) 7

Duration:

  • Limit to shortest duration possible (typically 2-5 days) 10, 3
  • Discontinue once normothermia achieved

Common Pitfalls to Avoid

  1. Treating fever to improve stroke outcomes - No evidence supports this; only treat for symptom relief 1

  2. Using standard oral dosing - Research supporting diclofenac in central fever used low-dose IV continuous infusion, not standard oral doses 3

  3. Ignoring cardiovascular risk - The cardiovascular risk is dose-independent and particularly dangerous in stroke patients 6

  4. Failing to monitor liver function - Hepatotoxicity can occur rapidly and without warning 7

  5. Assuming central fever diagnosis prematurely - Always exclude infection thoroughly first 8

  6. Combining with other hepatotoxic drugs - Avoid concurrent acetaminophen or other potentially hepatotoxic agents 7

Alternative Consideration

Recent case reports suggest gabapentin may have a role in central fever management 12, though this requires further investigation. Physical cooling methods remain an option when pharmacologic approaches are contraindicated.

Bottom Line

Given the lack of outcome benefit, significant cardiovascular risks (particularly in stroke patients), and hepatotoxicity concerns, diclofenac should be reserved only for refractory central fever causing significant patient discomfort when acetaminophen and physical cooling have failed, and only after careful cardiovascular and hepatic risk assessment. When used, employ low-dose IV continuous infusion (0.04 mg/kg/h) with close monitoring for the shortest duration possible 3, 5.

References

Research

High- vs. low-dose diclofenac and cardiovascular risks: a target trial emulation.

European heart journal. Cardiovascular pharmacotherapy, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.